

Technology Advisory Committee A Interests Register

Topic: Cemiplimab for treating cutaneous squamous cell carcinoma - CDF review of TA592 [ID3883]

Publication Date: Wednesday 29 June 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Andrew Sykes	Clinical expert	Direct financial	Dr Sykes has received honoraria of £420 from Sanofi for a lecture on cemiplimab that he gave in November 2021.	N/A	14.12.2021	N/A	It was agreed that her declarations would not prevent Dr Sykes from proving expert advice to the committee.